A Prospective Study of Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: The Keystone-001 Trial

Medicine, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology,
Esophageal Squamous Cell Carcinoma   Neoadjuvant Therapy   Pembrolizumab   Chemotherapy   Survival Rate  

Background and Research Motivation Esophageal Squamous Cell Carcinoma (ESCC) is a highly aggressive cancer, especially in locally advanced stages. Traditional neoadjuvant chemoradiotherapy (NCRT) is the standard treatment method for this type of cancer. Despite its significant therapeutic effects, local recurrence and distant metastasis rates remai...

HLA-A+ Tertiary Lymphoid Structures with Reactivated Tumor-Infiltrating Lymphocytes Are Associated with a Positive Immunotherapy Response in Esophageal Squamous Cell Carcinoma

Medicine, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology,
HLA-A+   Tertiary Lymphoid Structures   Esophageal Squamous Cell Carcinoma   Immunotherapy   Tumor-Infiltrating Lymphocytes   Antigen Presenting Machinery   Gene Expression  

In esophageal squamous cell carcinoma (ESCC), immune checkpoint blockade (ICB) therapy has achieved significant clinical benefits. However, the overall response rate to ICB treatment remains low. This study aims to identify biomarkers for ESCC response to ICB therapy and explore their potential clinical relevance. The authors of the paper come from...

Histone 3 Lysine 9 Acetylation-Specific Reprogramming Regulates Esophageal Squamous Cell Carcinoma Progression and Metastasis

Medicine, Basic Medical Sciences, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology,
Histone H3   Lysine 9 Acetylation   Esophageal Squamous Cell Carcinoma   Progression   Metastasis   Epigenetic Reprogramming  

The Mechanism of Action of Specific Reprogramming of Histone H3 Lysine 9 Acetylation (H3K9ac) in the Progression and Metastasis of Esophageal Squamous Cell Carcinoma (ESCC) Background Esophageal cancer is one of the most prevalent and invasive malignant tumors globally, causing over 500,000 cancer-related deaths annually, ranking sixth among cancer...

Romidepsin Exhibits Anti-Esophageal Squamous Cell Carcinoma Activity Through the DDIT4-mTORC1 Pathway

Medicine, Medical Laboratory Science, Oncology, Life Sciences, Cell Biology, Biochemistry,
Romidepsin   Esophageal Squamous Cell Carcinoma   DDIT4   mTORC1   Drug Screening   Apoptosis   Cell Cycle Arrest  

Romidepsin Exhibits Anti-Esophageal Squamous Cell Carcinoma Activity through DDIT4-mTORC1 Pathway Esophageal squamous cell carcinoma (ESCC) is one of the most common human malignancies globally, with high incidence and mortality rates. Given the limited current treatment options, there is an urgent need to develop new effective therapeutic drugs. I...